Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 3, 2003, Pages 403-408

  Edsbacker S ^a   Larsson, P ^b   Bergstrand, M ^b  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; HYDROCORTISONE; OMEPRAZOLE; PLACEBO;

ADRENAL DISEASE; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BONE DENSITY; BONE DISEASE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MEAN RESIDENCE TIME; NORMAL HUMAN; OUTCOMES RESEARCH; PHARYNGITIS; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTEMIC DISEASE; TIME; URINALYSIS; URINARY EXCRETION; URINARY TRACT INFECTION; VERTIGO;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTI-ULCER AGENTS; BUDESONIDE; CAPSULES; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; OMEPRAZOLE;

EID: 0037330355     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01431.x     Document Type: Article

References (32)

1. Spencer CM, McTavish D. Budesonide - A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995; 50: 854-72.
2. Brattsand R. Overview of newer glucocorticosteroid preparations for IBD. Can J Gastroenterol 1990; 4: 407-14.
3. Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf 1991; 6: 192-219.
4. Edsbäcker S. Budesonide capsules: scientific basis. Drugs Today 2000; 36: 9-23.
5. Edsbäcker S, Larsson P, Wollmer P. Gut delivery of budesonide, a topically active corticosteroid, from plain and controlled release capsules. Eur J Gastroenterol Hepatol 2002; 14: 1357-62.
6. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997; 41: 209-14.
7. Greenberg GR, Feagan BG, Martin F. et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331: 836-41.
8. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5.
9. Thomsen OØ, Cortot A, Jewell D. et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998; 339: 370-4.
10. Baert F, Schmit A, D'Haens G, et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology 2002; 122: 20-5.
11. Tromm A, Griga T, Mollmann HW, May B, Muller KM, Fisseler-Eckhoff A. Budesonide for the treatment of collagenous colitis: first results of a pilot trial. Am J Gastroenterol 1999; 94: 1871-5.
12. Clissold SP, Campoli-Richards DM. Omeprazole, a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986; 32: 15-47.
13. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 1997; 283: 434-42.
14. Jönsson G, Åstrom A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 1995; 23: 137-42.
15. Lindberg C, Blomqvist A, Paulson J. Determination of (22R,S) budesonide in human plasma by automated liquid chromatography/thermospray mass spectrometry. Biol Mass Spectrom 1992; 21: 525-33.
16. Belaiche J, Louis E. Corticosteroid treatment in active Crohn's disease. Acta Gastroenterol Belg 1998; 61: 153-7.
17. Hussain F, Trudgill N, Riley S. Mesalazine release from a pH-dependent formulation: effect of concurrent omeprazole administration. Gastroenterology 1995; 108: A840(Abstract).
18. Petersen KU. Omeprazole and the cytochrome P450 system. Aliment Pharmacol Ther 1995; 9: 1-9.
19. Press AG, Hauptmann IA, Hauptmann L, et al. pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1998; 12: 673-8.
20. Olbe L, Cederberg C, Lind T, Olausson M. Effect of omeprazole on gastric acid secretion and plasma gastrin. J Gastroenterol Hepatol 1989; 4(Suppl. 2): 19-25.
21. Olbe L, Lind T, Cederberg C, Ekenved G. Effect of omeprazole on gastric acid secretion in man. Scand J Gastroenterol Suppl 1986; 118: 105-7.
22. Prichard PJ, Yeomans ND, Mihaly GW, et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 1985; 88: 64-9.
23. Naesdal J, Bodemar G, Walan A. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. Scand J Gastroenterol 1984; 19: 916-22.
24. Sharma BK, Walt RP, Pounder RE, Gomes MD, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 1984; 25: 957-64.
25. Howden CW, Jones DB, Burget DW, Hunt RH. Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer. Gut 1986; 27: 1058-61.
26. Dressman JB, Bass P, Ritschel WA, Friend DR, Rubinstein A, Ziv E. Gastrointestinal parameters that influence oral medications. J Pharm Sci 1993; 82: 857-72.
27. Gan KH, Geus WP, Lamers CB, Heijerman HG. Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H. pylori-negative healthy subjects. Dig Dis Sci 1997; 42: 2304-9.
28. Hemery P, Galmiche JP, Roze C, et al. Low dose omeprazole: effects on gastric acid secretion in normal man. Gastroenterol Clin Biol 1987; 11: 148-53.
29. Naesdal J, Bankel M, Bodemar G, Gotthard R, Lundquist G, Walan A. The effect of 20 mg omeprazole daily on serum gastrin. 24-h intragastric acidity, and bile acid concentration in duodenal ulcer patients. Scand J Gastroenterol 1987; 22: 5-12.
30. Nakamura T, Arai Y, Tando Y, et al. Effect of omeprazole on changes in gastric and upper small intestine pH levels in patients with chronic pancreatitis. Clin Ther 1995; 17: 448-59.
31. Edsbäcker S, Wollmer P, Bengtsson B, Lundin P, Nilsson M. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther 2002 in press.
32. Abrahao LJ Jr, Abrahao LJ, Vargas C, Chagas V, Fogaca H. Gastroduodenal Crohn's disease - report of 4 cases and review of the literature. Arq Gastroenterol 2001; 38: 57-62 (in Portuguese).